Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 3, 2014, Pages 446-462

  Lee, Byung Cheol ^a,b   Lee, Jongsoon ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Kyung Hee University   (South Korea)

Author keywords

Adipose tissue; Adipose tissue immune cell; Insulin resistance; Obesity induced Inflammation

Indexed keywords

ADIPOSE TISSUE; B LYMPHOCYTE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; DENDRITIC CELL; EOSINOPHIL; HUMAN; IMMUNOCOMPETENT CELL; INSULIN RESISTANCE; LYMPHOCYTE; MACROPHAGE; MAST CELL; NATURAL KILLER T CELL; NEUTROPHIL; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TH1 CELL;

ABCA; ADIPOSE TISSUE; ADIPOSE TISSUE IMMUNE CELL; AIM; ANTIGEN-PRESENTING CELL; APC; APOPTOSIS INHIBITOR OF MACROPHAGE; APOPTOTIC SPECK PROTEIN CONTAINING A CASPASE RECRUITMENT DOMAIN; ASC; AT; AT MACROPHAGE; ATM; ATP-BINDING CASSETTE TRANSPORTER; BLT; BM; BMT; BONE MARROW; BONE MARROW TRANSPLANTATION; BREGS; C-C CHEMOKINE RECEPTOR TYPE 2; C-X-C MOTIF CHEMOKINE 5; C-X-C MOTIF RECEPTOR 2; CASP1; CASPASE 1; CCL5; CCR2; CHEMOKINE (C-C MOTIF) LIGAND 5; CLSS; CROWN-LIKE STRUCTURES; CTLS; CX3C CHEMOKINE RECEPTOR 1; CX3CR1; CXCL5; CXCR2; CYTOTOXIC T CELLS; DAMAGE-ASSOCIATED MOLECULAR PATTERN MOLECULES; DAMPS; DC; DENDRITIC CELLS; DOUBLE STRANDED DNA; DSDNA; ECM; EXTRACELLULAR MATRIX; FABP; FATTY-ACID-BINDING PROTEIN; FFA; FREE FATTY ACIDS; G-PROTEIN COUPLED RECEPTOR 120; GFP; GLUCOSE TRANSPORTER TYPE 4; GLUT4; GPR120; GREEN FLUORESCENT PROTEIN; HFD; HIGH FAT DIET; HIGH-MOBILITY GROUP BOX 1; HMGB1; IKKB; INHIBITOR OF ΚB KINASE-Β; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE; INSULIN RESISTANCE; IR; IRS; JNKS; JUN N-TERMINAL KINASES; KLF4; KRUEPPEL-LIKE FACTOR 4; LEUKOTRIENE B4 RECEPTOR; MACROPHAGE GALACTOSE-TYPE LECTIN 1; MAJOR HISTOCOMPATIBILITY COMPLEX; MAPK; MCP-1; MGL1; MHC; MITOGEN-ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN-1; MPO; MYELOPEROXIDASE; NATURAL KILLER T CELL; NE; NEUTROPHIL ELASTASE; NFKB; NKT; NLRP3; NLS; NOD-LIKE RECEPTOR FAMILY, PYRIN DOMAIN CONTAINING 3; NUCLEAR FACTOR KAPPA-LIGHT-CHAIN-ENHANCER OF ACTIVATED B CELLS; NUCLEAR LOCALIZATION SEQUENCE; OBESITY-INDUCED INFLAMMATION; PATTERN RECOGNITION RECEPTORS; PBMC; PERIPHERAL BLOOD MONONUCLEAR CELL; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PKC; PPAR; PROTEIN KINASE C; PRRS; RAGS; RANTES; REACTIVE OXYGEN SPECIES; RECOMBINATION ACTIVATING GENES; REGULATED ON ACTIVATION NORMAL T CELL EXPRESSED AND SECRETED; REGULATOR T CELLS; REGULATORY B CELLS; ROS; SOCS1; SORBIN AND SH3 DOMAIN-CONTAINING PROTEIN 1; SORBS1; STROMAL VASCULAR CELL; SUPPRESSOR OF CYTOKINE SIGNALING 1; SVC; T CELL RECEPTORS; T2D; TAMS; TCRS; THIAZOLIDINEDIONES; TLR; TNF; TOLL-LIKE RECEPTORS; TREG; TUMOR NECROSIS FACTORS; TUMOR-ASSOCIATED MACROPHAGES; TYPE 2 DIABETES; TZDS;

ADIPOSE TISSUE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MACROPHAGES; NEUTROPHILS; OBESITY; TH1 CELLS;

EID: 84893663418     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.05.017     Document Type: Review

References (171)

1. Kahn S.E., Hull R.L., Utzschneider K.M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444:840-846.
2. Biddinger S.B., Kahn C.R. From mice to men: insights into the insulin resistance syndromes. Annu. Rev. Physiol. 2006, 68:123-158.
3. White M.F. Insulin signaling in health and disease. Science 2003, 302:1710-1711.
4. Pilch P.F., Lee J. Insulin receptor family. Encyclopedia of Biological Chemistry 2004, vol. 2:436-440. Elsevier Science, San Diego.
5. Osborn O., Olefsky J.M. The cellular and signaling networks linking the immune system and metabolism in disease. Nat. Med. 2012, 18:363-374.
6. Choy E.H., Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 2001, 344:907-916.
7. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 352:1685-1695.
8. De Caterina R., Zampolli A. From asthma to atherosclerosis-5-lipoxygenase, leukotrienes, and inflammation. N. Engl. J. Med. 2004, 350:4-7.
9. Lee J. Adipose tissue macrophages in the development of obesity-induced inflammation, insulin resistance and Type 2 Diabetes. Arch. Pharmacal Res. 2013, 36:208-222.
10. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473:317-325.
11. Stephens J.M., Pekala P.H. Transcriptional repression of the C/EBP-alpha and GLUT4 genes in 3 T3-L1 adipocytes by tumor necrosis factor-alpha. Regulations is coordinate and independent of protein synthesis. J. Biol. Chem. 1992, 267:13580-13584.
12. Stephens J.M., Lee J., Pilch P.F. Tumor necrosis factor-alpha-induced insulin resistance in 3 T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J. Biol. Chem. 1997, 272:971-976.
13. Cheung A.T., Ree D., Kolls J.K., Fuselier J., Coy D.H., Bryer-Ash M. An in vivo model for elucidation of the mechanism of tumor necrosis factor-alpha (TNF-alpha)-induced insulin resistance: evidence for differential regulation of insulin signaling by TNF-alpha. Endocrinology 1998, 139:4928-4935.
14. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
15. Uysal K.T., Wiesbrock S.M., Marino M.W., Hotamisligil G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997, 389:610-614.
16. Ventre J., Doebber T., Wu M., MacNaul K., Stevens K., Pasparakis M., Kollias G., Moller D.E. Targeted disruption of the tumor necrosis factor-alpha gene: metabolic consequences in obese and nonobese mice. Diabetes 1997, 46:1526-1531.
17. De Taeye B.M., Novitskaya T., McGuinness O.P., Gleaves L., Medda M., Covington J.W., Vaughan D.E. Macrophage TNF-alpha contributes to insulin resistance and hepatic steatosis in diet-induced obesity. Am. J. Physiol. Endocrinol. Metab. 2007, 293:E713-E725.
18. Festa A., D'Agostino R., Howard G., Mykkanen L., Tracy R.P., Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102:42-47.
19. Yudkin J.S., Kumari M., Humphries S.E., Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis 2000, 148:209-214.
20. Barzilay J.I., Abraham L., Heckbert S.R., Cushman M., Kuller L.H., Resnick H.E., Tracy R.P. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001, 50:2384-2389.
21. Ford E.S. Leukocyte count, erythrocyte sedimentation rate, and diabetes incidence in a national sample of US adults. Am. J. Epidemiol. 2002, 155:57-64.
22. Freeman D.J., Norrie J., Caslake M.J., Gaw A., Ford I., Lowe G.D., O'Reilly D.S., Packard C.J., Sattar N. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002, 51:1596-1600.
23. Pickup J.C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004, 27:813-823.
24. Pradhan A.D., Cook N.R., Buring J.E., Manson J.E., Ridker P.M. C-reactive protein is independently associated with fasting insulin in nondiabetic women. Arterioscler. Thromb. Vasc. Biol. 2003, 23:650-655.
25. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
26. Schmidt M.I., Duncan B.B., Sharrett A.R., Lindberg G., Savage P.J., Offenbacher S., Azambuja M.I., Tracy R.P., Heiss G. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999, 353:1649-1652.
27. Vozarova B., Weyer C., Lindsay R.S., Pratley R.E., Bogardus C., Tataranni P.A. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002, 51:455-461.
28. Barzilay J., Freedland E. Inflammation and its association with glucose disorders and cardiovascular disease. Treat. Endocrinol. 2003, 2:85-94.
29. Duncan B.B., Schmidt M.I., Pankow J.S., Ballantyne C.M., Couper D., Vigo A., Hoogeveen R., Folsom A.R., Heiss G. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2003, 52:1799-1805.
30. Kim J.K., Kim Y.J., Fillmore J.J., Chen Y., Moore I., Lee J., Yuan M., Li Z.W., Karin M., Perret P., Shoelson S.E., Shulman G.I. Prevention of fat-induced insulin resistance by salicylate. J. Clin. Invest. 2001, 108:437-446.
31. Yuan M., Konstantopoulos N., Lee J., Hansen L., Li Z.W., Karin M., Shoelson S.E. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001, 293:1673-1677.
32. Fleischman A., Shoelson S.E., Bernier R., Goldfine A.B. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008, 31:289-294.
33. Goldfine A.B., Fonseca V., Jablonski K.A., Pyle L., Staten M.A., Shoelson S.E. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann. Intern. Med. 2010, 152:346-357.
34. Goldfine A.B., Silver R., Aldhahi W., Cai D., Tatro E., Lee J., Shoelson S.E. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin. Transl. Sci. 2008, 1:36-43.
35. Hundal R.S., Petersen K.F., Mayerson A.B., Randhawa P.S., Inzucchi S., Shoelson S.E., Shulman G.I. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J. Clin. Invest. 2002, 109:1321-1326.
36. Lumeng C.N., Saltiel A.R. Inflammatory links between obesity and metabolic disease. J. Clin. Invest. 2011, 121:2111-2117.
37. Gregor M.F., Hotamisligil G.S. Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 2011, 29:415-445.
38. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., Sole J., Nichols A., Ross J.S., Tartaglia L.A., Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 2003, 112:1821-1830.
39. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 2003, 112:1796-1808.
40. Ferrante A.W. Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. J. Intern. Med. 2007, 262:408-414.
41. Solinas G., Karin M. JNK1 and IKKbeta: molecular links between obesity and metabolic dysfunction. FASEB J. 2010, 24:2596-2611.
42. Odegaard J.I., Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science 2013, 339:172-177.
43. Walther T.C., Farese R.V. Lipid droplets and cellular lipid metabolism. Annu. Rev. Biochem. 2012, 81:687-714.
44. Herrero L., Shapiro H., Nayer A., Lee J., Shoelson S.E. Inflammation and adipose tissue macrophages in lipodystrophic mice. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:240-245.
45. Ouchi N., Parker J.L., Lugus J.J., Walsh K. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 2011, 11:85-97.
46. Kondo M., Wagers A.J., Manz M.G., Prohaska S.S., Scherer D.C., Beilhack G.F., Shizuru J.A., Weissman I.L. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu. Rev. Immunol. 2003, 21:759-806.
47. Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005, 5:953-964.
48. Murdoch C., Muthana M., Coffelt S.B., Lewis C.E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 2008, 8:618-631.
49. Glass C.K., Olefsky J.M. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 2012, 15:635-645.
50. Kanda H., Tateya S., Tamori Y., Kotani K., Hiasa K., Kitazawa R., Kitazawa S., Miyachi H., Maeda S., Egashira K., Kasuga M. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Invest. 2006, 116:1494-1505.
51. Kamei N., Tobe K., Suzuki R., Ohsugi M., Watanabe T., Kubota N., Ohtsuka-Kowatari N., Kumagai K., Sakamoto K., Kobayashi M., Yamauchi T., Ueki K., Oishi Y., Nishimura S., Manabe I., Hashimoto H., Ohnishi Y., Ogata H., Tokuyama K., Tsunoda M., Ide T., Murakami K., Nagai R., Kadowaki T. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J. Biol. Chem. 2006, 281:26602-26614.
52. Lumeng C.N., Bodzin J.L., Saltiel A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 2007, 117:175-184.
53. Dominguez P.M., Ardavin C. Differentiation and function of mouse monocyte-derived dendritic cells in steady state and inflammation. Immunol. Rev. 2010, 234:90-104.
54. Gautier E.L., Shay T., Miller J., Greter M., Jakubzick C., Ivanov S., Helft J., Chow A., Elpek K.G., Gordonov S., Mazloom A.R., Ma'ayan A., Chua W.J., Hansen T.H., Turley S.J., Merad M., Randolph G.J., Best A.J., Knell J., Goldrath A., Brown B., Jojic V., Koller D., Cohen N., Brennan P., Brenner M., Regev A., Fletcher A., Elpek K., Bellemare-Pelletier A., Malhotra D., Turley S., Jianu R., Laidlaw D., Collins J., Narayan K., Sylvia K., Kang J., Gazit R., Garrison B.S., Rossi D.J., Kim F., Rao T.N., Wagers A., Shinton S.A., Hardy R.R., Monach P., Bezman N.A., Sun J.C., Kim C.C., Lanier L.L., Heng T., Kreslavsky T., Painter M., Ericson J., Davis S., Mathis D., Benoist C. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat. Immunol. 2012, 13:1118-1128.
55. Hashimoto D., Miller J., Merad M. Dendritic cell and macrophage heterogeneity in vivo. Immunity 2011, 35:323-335.
56. Shaul M.E., Bennett G., Strissel K.J., Greenberg A.S., Obin M.S. Dynamic, M2-like remodeling phenotypes of CD11c+ adipose tissue macrophages during high-fat diet-induced obesity in mice. Diabetes 2010, 59:1171-1181.
57. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 2003, 3:23-35.
58. Bourlier V., Zakaroff-Girard A., Miranville A., De Barros S., Maumus M., Sengenes C., Galitzky J., Lafontan M., Karpe F., Frayn K.N., Bouloumie A. Remodeling phenotype of human subcutaneous adipose tissue macrophages. Circulation 2008, 117:806-815.
59. Mayi T.H., Daoudi M., Derudas B., Gross B., Bories G., Wouters K., Brozek J., Caiazzo R., Raverdi V., Pigeyre M., Allavena P., Mantovani A., Pattou F., Staels B., Chinetti-Gbaguidi G. Human adipose tissue macrophages display activation of cancer-related pathways. J. Biol. Chem. 2012, 287:21904-21913.
60. Cinti S., Mitchell G., Barbatelli G., Murano I., Ceresi E., Faloia E., Wang S., Fortier M., Greenberg A.S., Obin M.S. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res. 2005, 46:2347-2355.
61. Steinman R.M. Dendritic cells in vivo: a key target for a new vaccine science. Immunity 2008, 29:319-324.
62. Patsouris D., Li P.P., Thapar D., Chapman J., Olefsky J.M., Neels J.G. Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab. 2008, 8:301-309.
63. Stefanovic-Racic M., Yang X., Turner M.S., Mantell B.S., Stolz D.B., Sumpter T.L., Sipula I.J., Dedousis N., Scott D.K., Morel P.A., Thomson A.W., O'Doherty R.M. Dendritic cells promote macrophage infiltration and comprise a substantial proportion of obesity-associated increases in CD11c+ cells in adipose tissue and liver. Diabetes 2012, 61:2330-2339.
64. Bertola A., Ciucci T., Rousseau D., Bourlier V., Duffaut C., Bonnafous S., Blin-Wakkach C., Anty R., Iannelli A., Gugenheim J., Tran A., Bouloumie A., Gual P., Wakkach A. Identification of adipose tissue dendritic cells correlated with obesity-associated insulin-resistance and inducing Th17 responses in mice and patients. Diabetes 2012, 61:2238-2247.
65. Jaensson E., Uronen-Hansson H., Pabst O., Eksteen B., Tian J., Coombes J.L., Berg P.L., Davidsson T., Powrie F., Johansson-Lindbom B., Agace W.W. Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans. J. Exp. Med. 2008, 205:2139-2149.
66. Winer D.A., Winer S., Shen L., Wadia P.P., Yantha J., Paltser G., Tsui H., Wu P., Davidson M.G., Alonso M.N., Leong H.X., Glassford A., Caimol M., Kenkel J.A., Tedder T.F., McLaughlin T., Miklos D.B., Dosch H.M., Engleman E.G. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat. Med. 2011, 17:610-617.
67. DeFuria J., Belkina A.C., Jagannathan-Bogdan M., Snyder-Cappione J., Carr J.D., Nersesova Y., Markham D., Strissel K.J., Watkins A., Zhu M., Allen J., Bouchard J., Toraldo D., Jasuja R., Obin M.S., McDonnell M.E., Apovian C., Denis G.V., Nikolajczyk B.S. B cells promote inflammation in obesity and type 2 diabetes through regulation of T cell function and an inflammatory cytokine profile. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:5133-5138.
68. Mantovani A., Cassatella M.A., Costantini C., Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat. Rev. Immunol. 2011, 11:519-531.
69. Amulic B., Cazalet C., Hayes G.L., Metzler K.D., Zychlinsky A. Neutrophil function: from mechanisms to disease. Annu. Rev. Immunol. 2012, 30:459-489.
70. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat. Rev. Immunol. 2006, 6:173-182.
71. Elgazar-Carmon V., Rudich A., Hadad N., Levy R. Neutrophils transiently infiltrate intra-abdominal fat early in the course of high-fat feeding. J. Lipid Res. 2008, 49:1894-1903.
72. Talukdar S., Oh da Y., Bandyopadhyay G., Li D., Xu J., McNelis J., Lu M., Li P., Yan Q., Zhu Y., Lin M., Brenner M.B., Olefsky J.M. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat. Med. 2012, 18:1407-1412.
73. Spencer L.A., Weller P.F. Eosinophils and Th2 immunity: contemporary insights. Immunol. Cell Biol. 2010, 88:250-256.
74. Rothenberg M.E., Hogan S.P. The eosinophil. Annu. Rev. Immunol. 2006, 24:147-174.
75. Ricardo-Gonzalez R.R., Red Eagle A., Odegaard J.I., Jouihan H., Morel C.R., Heredia J.E., Mukundan L., Wu D., Locksley R.M., Chawla A. IL-4/STAT6 immune axis regulates peripheral nutrient metabolism and insulin sensitivity. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:22617-22622.
76. Wu D., Molofsky A.B., Liang H.E., Ricardo-Gonzalez R.R., Jouihan H.A., Bando J.K., Chawla A., Locksley R.M. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 2011, 332:243-247.
77. Abraham S.N., St John A.L. Mast cell-orchestrated immunity to pathogens. Nat. Rev. Immunol. 2010, 10:440-452.
78. Galli S.J., Kalesnikoff J., Grimbaldeston M.A., Piliponsky A.M., Williams C.M., Tsai M. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu. Rev. Immunol. 2005, 23:749-786.
79. Liu J., Divoux A., Sun J., Zhang J., Clement K., Glickman J.N., Sukhova G.K., Wolters P.J., Du J., Gorgun C.Z., Doria A., Libby P., Blumberg R.S., Kahn B.B., Hotamisligil G.S., Shi G.P. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat. Med. 2009, 15:940-945.
80. Koch U., Radtke F. Mechanisms of T cell development and transformation. Annu. Rev. Cell Dev. Biol. 2011, 27:539-562.
81. Oestreich K.J., Weinmann A.S. Master regulators or lineage-specifying? Changing views on CD4+ T cell transcription factors. Nat. Rev. Immunol. 2012, 12:799-804.
82. Zhang N., Bevan M.J. CD8(+) T cells: foot soldiers of the immune system. Immunity 2011, 35:161-168.
83. Winer S., Chan Y., Paltser G., Truong D., Tsui H., Bahrami J., Dorfman R., Wang Y., Zielenski J., Mastronardi F., Maezawa Y., Drucker D.J., Engleman E., Winer D., Dosch H.M. Normalization of obesity-associated insulin resistance through immunotherapy. Nat. Med. 2009, 15:921-929.
84. Rocha V.Z., Folco E.J., Sukhova G., Shimizu K., Gotsman I., Vernon A.H., Libby P. Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circ. Res. 2008, 103:467-476.
85. Yang H., Youm Y.H., Vandanmagsar B., Ravussin A., Gimble J.M., Greenway F., Stephens J.M., Mynatt R.L., Dixit V.D. Obesity increases the production of proinflammatory mediators from adipose tissue T cells and compromises TCR repertoire diversity: implications for systemic inflammation and insulin resistance. J. Immunol. 2010, 185:1836-1845.
86. Nishimura S., Manabe I., Nagasaki M., Eto K., Yamashita H., Ohsugi M., Otsu M., Hara K., Ueki K., Sugiura S., Yoshimura K., Kadowaki T., Nagai R. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat. Med. 2009, 15:914-920.
87. Feuerer M., Herrero L., Cipolletta D., Naaz A., Wong J., Nayer A., Lee J., Goldfine A.B., Benoist C., Shoelson S., Mathis D. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 2009, 15:930-939.
88. Josefowicz S.Z., Lu L.F., Rudensky A.Y. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 2012, 30:531-564.
89. Cipolletta D., Feuerer M., Li A., Kamei N., Lee J., Shoelson S.E., Benoist C., Mathis D. PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 2012, 486:549-553.
90. De Libero G., Mori L. Recognition of lipid antigens by T cells. Nat. Rev. Immunol. 2005, 5:485-496.
91. Lynch L., Nowak M., Varghese B., Clark J., Hogan A.E., Toxavidis V., Balk S.P., O'Shea D., O'Farrelly C., Exley M.A. Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. Immunity 2012, 37:574-587.
92. Wu L., Parekh V.V., Gabriel C.L., Bracy D.P., Marks-Shulman P.A., Tamboli R.A., Kim S., Mendez-Fernandez Y.V., Besra G.S., Lomenick J.P., Williams B., Wasserman D.H., Van Kaer L. Activation of invariant natural killer T cells by lipid excess promotes tissue inflammation, insulin resistance, and hepatic steatosis in obese mice. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E1143-E1152.
93. Kotas M.E., Lee H.Y., Gillum M.P., Annicelli C., Guigni B.A., Shulman G.I., Medzhitov R. Impact of CD1d deficiency on metabolism. PLoS One 2011, 6:e25478.
94. Mantell B.S., Stefanovic-Racic M., Yang X., Dedousis N., Sipula I.J., O'Doherty R.M. Mice lacking NKT cells but with a complete complement of CD8+ T-cells are not protected against the metabolic abnormalities of diet-induced obesity. PLoS One 2011, 6:e19831.
95. Ji Y., Sun S., Xia S., Yang L., Li X., Qi L. Short term high fat diet challenge promotes alternative macrophage polarization in adipose tissue via natural killer T cells and interleukin-4. J. Biol. Chem. 2012, 287:24378-24386.
96. Ji Y., Sun S., Xu A., Bhargava P., Yang L., Lam K.S., Gao B., Lee C.H., Kersten S., Qi L. Activation of natural killer T cells promotes M2 Macrophage polarization in adipose tissue and improves systemic glucose tolerance via interleukin-4 (IL-4)/STAT6 protein signaling axis in obesity. J. Biol. Chem. 2012, 287:13561-13571.
97. Ohmura K., Ishimori N., Ohmura Y., Tokuhara S., Nozawa A., Horii S., Andoh Y., Fujii S., Iwabuchi K., Onoe K., Tsutsui H. Natural killer T cells are involved in adipose tissues inflammation and glucose intolerance in diet-induced obese mice. Arterioscler. Thromb. Vasc. Biol. 2010, 30:193-199.
98. Schipper H.S., Rakhshandehroo M., van de Graaf S.F., Venken K., Koppen A., Stienstra R., Prop S., Meerding J., Hamers N., Besra G., Boon L., Nieuwenhuis E.E., Elewaut D., Prakken B., Kersten S., Boes M., Kalkhoven E. Natural killer T cells in adipose tissue prevent insulin resistance. J. Clin. Invest. 2012, 122:3343-3354.
99. Huh J.Y., Kim J.I., Park Y.J., Hwang I.J., Lee Y.S., Sohn J.H., Lee S.K., Alfadda A.A., Kim S.S., Choi S.H., Lee D.S., Park S.H., Seong R.H., Choi C.S., Kim J.B. A novel function of adipocytes in lipid antigen presentation to iNKT cells. Mol. Cell. Biol. 2013, 33:328-339.
100. Van Kaer L. Natural killer T cells as targets for immunotherapy of autoimmune diseases. Immunol. Cell Biol. 2004, 82:315-322.
101. Carnaud C., Lee D., Donnars O., Park S.H., Beavis A., Koezuka Y., Bendelac A. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 1999, 163:4647-4650.
102. Singh N., Hong S., Scherer D.C., Serizawa I., Burdin N., Kronenberg M., Koezuka Y., Van Kaer L. Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J. Immunol. 1999, 163:2373-2377.
103. Matsuda J.L., Naidenko O.V., Gapin L., Nakayama T., Taniguchi M., Wang C.R., Koezuka Y., Kronenberg M. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 2000, 192:741-754.
104. Eberl G., Brawand P., MacDonald H.R. Selective bystander proliferation of memory CD4+ and CD8+ T cells upon NK T or T cell activation. J. Immunol. 2000, 165:4305-4311.
105. Sidobre S., Naidenko O.V., Sim B.C., Gascoigne N.R., Garcia K.C., Kronenberg M. The V alpha 14 NKT cell TCR exhibits high-affinity binding to a glycolipid/CD1d complex. J. Immunol. 2002, 169:1340-1348.
106. LeBien T.W., Tedder T.F. B lymphocytes: how they develop and function. Blood 2008, 112:1570-1580.
107. Mauri C., Bosma A. Immune regulatory function of B cells. Annu. Rev. Immunol. 2012, 30:221-241.
108. Oeckinghaus A., Hayden M.S., Ghosh S. Crosstalk in NF-kappaB signaling pathways. Nat. Immunol. 2011, 12:695-708.
109. Ghosh G., Wang V.Y., Huang D.B., Fusco A. NF-kappaB regulation: lessons from structures. Immunol. Rev. 2012, 246:36-58.
110. Arkan M.C., Hevener A.L., Greten F.R., Maeda S., Li Z.W., Long J.M., Wynshaw-Boris A., Poli G., Olefsky J., Karin M. IKK-beta links inflammation to obesity-induced insulin resistance. Nat. Med. 2005, 11:191-198.
111. Beutler B.A. TLRs and innate immunity. Blood 2009, 113:1399-1407.
112. Shi H., Kokoeva M.V., Inouye K., Tzameli I., Yin H., Flier J.S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 2006, 116:3015-3025.
113. Lee J.Y., Sohn K.H., Rhee S.H., Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J. Biol. Chem. 2001, 276:16683-16689.
114. Tsukumo D.M., Carvalho-Filho M.A., Carvalheira J.B., Prada P.O., Hirabara S.M., Schenka A.A., Araujo E.P., Vassallo J., Curi R., Velloso L.A., Saad M.J. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 2007, 56:1986-1998.
115. Holland W.L., Bikman B.T., Wang L.P., Yuguang G., Sargent K.M., Bulchand S., Knotts T.A., Shui G., Clegg D.J., Wenk M.R., Pagliassotti M.J., Scherer P.E., Summers S.A. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. J. Clin. Invest. 2011, 121:1858-1870.
116. Saberi M., Woods N.B., de Luca C., Schenk S., Lu J.C., Bandyopadhyay G., Verma I.M., Olefsky J.M. Hematopoietic cell-specific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metab. 2009, 10:419-429.
117. Orr J.S., Puglisi M.J., Ellacott K.L., Lumeng C.N., Wasserman D.H., Hasty A.H. Toll-like receptor 4 deficiency promotes the alternative activation of adipose tissue macrophages. Diabetes 2012, 61:2718-2727.
118. Hosoi T., Yokoyama S., Matsuo S., Akira S., Ozawa K. Myeloid differentiation factor 88 (MyD88)-deficiency increases risk of diabetes in mice. PLoS One 2010, 5:e12537.
119. Bogoyevitch M.A., Ngoei K.R., Zhao T.T., Yeap Y.Y., Ng D.C. c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges. Biochim. Biophys. Acta 2010, 1804:463-475.
120. Hotamisligil G.S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010, 140:900-917.
121. Hirosumi J., Tuncman G., Chang L., Gorgun C.Z., Uysal K.T., Maeda K., Karin M., Hotamisligil G.S. A central role for JNK in obesity and insulin resistance. Nature 2002, 420:333-336.
122. Jaeschke A., Czech M.P., Davis R.J. An essential role of the JIP1 scaffold protein for JNK activation in adipose tissue. Genes Dev. 2004, 18:1976-1980.
123. Solinas G., Vilcu C., Neels J.G., Bandyopadhyay G.K., Luo J.L., Naugler W., Grivennikov S., Wynshaw-Boris A., Scadeng M., Olefsky J.M., Karin M. JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab. 2007, 6:386-397.
124. Vallerie S.N., Furuhashi M., Fucho R., Hotamisligil G.S. A predominant role for parenchymal c-Jun amino terminal kinase (JNK) in the regulation of systemic insulin sensitivity. PLoS One 2008, 3:e3151.
125. Sabio G., Das M., Mora A., Zhang Z., Jun J.Y., Ko H.J., Barrett T., Kim J.K., Davis R.J. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008, 322:1539-1543.
126. Han M.S., Jung D.Y., Morel C., Lakhani S.A., Kim J.K., Flavell R.A., Davis R.J. JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation. Science 2013, 339:218-222.
127. Strowig T., Henao-Mejia J., Elinav E., Flavell R. Inflammasomes in health and disease. Nature 2012, 481:278-286.
128. Davis B.K., Wen H., Ting J.P. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu. Rev. Immunol. 2011, 29:707-735.
129. Duewell P., Kono H., Rayner K.J., Sirois C.M., Vladimer G., Bauernfeind F.G., Abela G.S., Franchi L., Nunez G., Schnurr M., Espevik T., Lien E., Fitzgerald K.A., Rock K.L., Moore K.J., Wright S.D., Hornung V., Latz E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361.
130. Wen H., Gris D., Lei Y., Jha S., Zhang L., Huang M.T., Brickey W.J., Ting J.P. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 2011, 12:408-415.
131. Vandanmagsar B., Youm Y.H., Ravussin A., Galgani J.E., Stadler K., Mynatt R.L., Ravussin E., Stephens J.M., Dixit V.D. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 2011, 17:179-188.
132. Stienstra R., van Diepen J.A., Tack C.J., Zaki M.H., van de Veerdonk F.L., Perera D., Neale G.A., Hooiveld G.J., Hijmans A., Vroegrijk I., van den Berg S., Romijn J., Rensen P.C., Joosten L.A., Netea M.G., Kanneganti T.D. Inflammasome is a central player in the induction of obesity and insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:15324-15329.
133. Jager J., Gremeaux T., Cormont M., Le Marchand-Brustel Y., Tanti J.F. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 2007, 148:241-251.
134. Lagathu C., Yvan-Charvet L., Bastard J.P., Maachi M., Quignard-Boulange A., Capeau J., Caron M. Long-term treatment with interleukin-1beta induces insulin resistance in murine and human adipocytes. Diabetologia 2006, 49:2162-2173.
135. Osborn O., Brownell S.E., Sanchez-Alavez M., Salomon D., Gram H., Bartfai T. Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity. Cytokine 2008, 44:141-148.
136. Larsen C.M., Faulenbach M., Vaag A., Volund A., Ehses J.A., Seifert B., Mandrup-Poulsen T., Donath M.Y. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 2007, 356:1517-1526.
137. Ridker P.M., Howard C.P., Walter V., Everett B., Libby P., Hensen J., Thuren T. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 2012, 126:2739-2748.
138. Rui L., Aguirre V., Kim J.K., Shulman G.I., Lee A., Corbould A., Dunaif A., White M.F. Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J. Clin. Invest. 2001, 107:181-189.
139. Ofei F., Hurel S., Newkirk J., Sopwith M., Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996, 45:881-885.
140. Paquot N., Castillo M.J., Lefebvre P.J., Scheen A.J. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J. Clin. Endocrinol. Metab. 2000, 85:1316-1319.
141. Hong E.G., Ko H.J., Cho Y.R., Kim H.J., Ma Z., Yu T.Y., Friedline R.H., Kurt-Jones E., Finberg R., Fischer M.A., Granger E.L., Norbury C.C., Hauschka S.D., Philbrick W.M., Lee C.G., Elias J.A., Kim J.K. Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle. Diabetes 2009, 58:2525-2535.
142. Wallenius V., Wallenius K., Ahren B., Rudling M., Carlsten H., Dickson S.L., Ohlsson C., Jansson J.O. Interleukin-6-deficient mice develop mature-onset obesity. Nat. Med. 2002, 8:75-79.
143. Fujisaka S., Usui I., Bukhari A., Ikutani M., Oya T., Kanatani Y., Tsuneyama K., Nagai Y., Takatsu K., Urakaze M., Kobayashi M., Tobe K. Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes 2009, 58:2574-2582.
144. Kowalski G.M., Nicholls H.T., Risis S., Watson N.K., Kanellakis P., Bruce C.R., Bobik A., Lancaster G.I., Febbraio M.A. Deficiency of haematopoietic-cell-derived IL-10 does not exacerbate high-fat-diet-induced inflammation or insulin resistance in mice. Diabetologia 2011, 54:888-899.
145. Honda K., Littman D.R. The microbiome in infectious disease and inflammation. Annu. Rev. Immunol. 2012, 30:759-795.
146. Tilg H., Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J. Clin. Invest. 2011, 121:2126-2132.
147. Odegaard J.I., Ricardo-Gonzalez R.R., Goforth M.H., Morel C.R., Subramanian V., Mukundan L., Red Eagle A., Vats D., Brombacher F., Ferrante A.W., Chawla A. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007, 447:1116-1120.
148. -/- bone marrow. J. Lipid Res. 2009, 50:214-224.
149. Caricilli A.M., Picardi P.K., de Abreu L.L., Ueno M., Prada P.O., Ropelle E.R., Hirabara S.M., Castoldi A., Vieira P., Camara N.O., Curi R., Carvalheira J.B., Saad M.J. Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice. PLoS Biol. 2011, 9:e1001212.
150. Zhang X., Xu A., Chung S.K., Cresser J.H., Sweeney G., Wong R.L., Lin A., Lam K.S. Selective inactivation of c-Jun NH2-terminal kinase in adipose tissue protects against diet-induced obesity and improves insulin sensitivity in both liver and skeletal muscle in mice. Diabetes 2011, 60:486-495.
151. Barra N.G., Reid S., MacKenzie R., Werstuck G., Trigatti B.L., Richards C., Holloway A.C., Ashkar A.A. Interleukin-15 contributes to the regulation of murine adipose tissue and human adipocytes. Obesity (Silver Spring) 2010, 18:1601-1607.
152. Chang Y.H., Ho K.T., Lu S.H., Huang C.N., Shiau M.Y. Regulation of glucose/lipid metabolism and insulin sensitivity by interleukin-4. Int. J. Obes. (Lond) 2012, 36:993-998.
153. McGillicuddy F.C., Harford K.A., Reynolds C.M., Oliver E., Claessens M., Mills K.H., Roche H.M. Lack of interleukin-1 receptor I (IL-1RI) protects mice from high-fat diet-induced adipose tissue inflammation coincident with improved glucose homeostasis. Diabetes 2011, 60:1688-1698.
154. Morris D.L., Oatmen K.E., Wang T., DelProposto J.L., Lumeng C.N. CX3CR1 deficiency does not influence trafficking of adipose tissue macrophages in mice with diet-induced obesity. Obesity 2012, 20:1189-1199.
155. Nomiyama T., Perez-Tilve D., Ogawa D., Gizard F., Zhao Y., Heywood E.B., Jones K.L., Kawamori R., Cassis L.A., Tschop M.H., Bruemmer D. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J. Clin. Invest. 2007, 117:2877-2888.
156. Weisberg S.P., Hunter D., Huber R., Lemieux J., Slaymaker S., Vaddi K., Charo I., Leibel R.L., Ferrante A.W. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest. 2006, 116:115-124.
157. Chavey C., Lazennec G., Lagarrigue S., Clape C., Iankova I., Teyssier J., Annicotte J.S., Schmidt J., Mataki C., Yamamoto H., Sanches R., Guma A., Stich V., Vitkova M., Jardin-Watelet B., Renard E., Strieter R., Tuthill A., Hotamisligil G.S., Vidal-Puig A., Zorzano A., Langin D., Fajas L. CXC ligand 5 is an adipose-tissue derived factor that links obesity to insulin resistance. Cell Metab. 2009, 9:339-349.
158. Kang K., Reilly S.M., Karabacak V., Gangl M.R., Fitzgerald K., Hatano B., Lee C.H. Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab. 2008, 7:485-495.
159. Kurokawa J., Nagano H., Ohara O., Kubota N., Kadowaki T., Arai S., Miyazaki T. Apoptosis inhibitor of macrophage (AIM) is required for obesity-associated recruitment of inflammatory macrophages into adipose tissue. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:12072-12077.
160. Watanabe Y., Nakamura T., Ishikawa S., Fujisaka S., Usui I., Tsuneyama K., Ichihara Y., Wada T., Hirata Y., Suganami T., Izaki H., Akira S., Miyake K., Kanayama H.O., Shimabukuro M., Sata M., Sasaoka T., Ogawa Y., Tobe K., Takatsu K., Nagai Y. The radioprotective 105/MD-1 complex contributes to diet-induced obesity and adipose tissue inflammation. Diabetes 2012, 61:1199-1209.
161. Westcott D.J., Delproposto J.B., Geletka L.M., Wang T., Singer K., Saltiel A.R., Lumeng C.N. MGL1 promotes adipose tissue inflammation and insulin resistance by regulating 7/4hi monocytes in obesity. J. Exp. Med. 2009, 206:3143-3156.
162. Nicholls H.T., Kowalski G., Kennedy D.J., Risis S., Zaffino L.A., Watson N., Kanellakis P., Watt M.J., Bobik A., Bonen A., Febbraio M., Lancaster G.I., Febbraio M.A. Hematopoietic cell-restricted deletion of CD36 reduces high-fat diet-induced macrophage infiltration and improves insulin signaling in adipose tissue. Diabetes 2011, 60:1100-1110.
163. Spite M., Hellmann J., Tang Y., Mathis S.P., Kosuri M., Bhatnagar A., Jala V.R., Haribabu B. Deficiency of the leukotriene B4 receptor, BLT-1, protects against systemic insulin resistance in diet-induced obesity. J. Immunol. 2011, 187:1942-1949.
164. Sachithanandan N., Graham K.L., Galic S., Honeyman J.E., Fynch S.L., Hewitt K.A., Steinberg G.R., Kay T.W. Macrophage deletion of SOCS1 increases sensitivity to LPS and palmitic acid and results in systemic inflammation and hepatic insulin resistance. Diabetes 2011, 60:2023-2031.
165. Mauer J., Chaurasia B., Plum L., Quast T., Hampel B., Bluher M., Kolanus W., Kahn C.R., Bruning J.C. Myeloid cell-restricted insulin receptor deficiency protects against obesity-induced inflammation and systemic insulin resistance. PLoS Genet. 2010, 6:e1000938.
166. Zhu X., Lee J.Y., Timmins J.M., Brown J.M., Boudyguina E., Mulya A., Gebre A.K., Willingham M.C., Hiltbold E.M., Mishra N., Maeda N., Parks J.S. Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages. J. Biol. Chem. 2008, 283:22930-22941.
167. Lesniewski L.A., Hosch S.E., Neels J.G., de Luca C., Pashmforoush M., Lumeng C.N., Chiang S.H., Scadeng M., Saltiel A.R., Olefsky J.M. Bone marrow-specific Cap gene deletion protects against high-fat diet-induced insulin resistance. Nat. Med. 2007, 13:455-462.
168. Furuhashi M., Fucho R., Gorgun C.Z., Tuncman G., Cao H., Hotamisligil G.S. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J. Clin. Invest. 2008, 118:2640-2650.
169. Liao X., Sharma N., Kapadia F., Zhou G., Lu Y., Hong H., Paruchuri K., Mahabeleshwar G.H., Dalmas E., Venteclef N., Flask C.A., Kim J., Doreian B.W., Lu K.Q., Kaestner K.H., Hamik A., Clement K., Jain M.K. Kruppel-like factor 4 regulates macrophage polarization. J. Clin. Invest. 2011, 121:2736-2749.
170. Feral C.C., Neels J.G., Kummer C., Slepak M., Olefsky J.M., Ginsberg M.H. Blockade of alpha4 integrin signaling ameliorates the metabolic consequences of high-fat diet-induced obesity. Diabetes 2008, 57:1842-1851.
171. Oh D.Y., Talukdar S., Bae E.J., Imamura T., Morinaga H., Fan W., Li P., Lu W.J., Watkins S.M., Olefsky J.M. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010, 142:687-698.